|
Market Cap (5-Jul) $2,416,092 (1,016th) |
Close (30-Jun) $0.016 |
Volume (30-Jun) 5,525,026 |
Shortsold (24-Dec) 11,970 (0.01%) (590th) |
|
52w High $0.082 |
52w Low $0.011 |
P/E - |
EPS -0.05 |
IBX released this announcement to the ASX on 24 February 2022, 13:57. The announcement is not marked as price sensitive, and is 61 page(s) in length and 3.11MB in size.
You can view all announcements from IBX and see how they appear on a price chart on the announcements page.
At the date of this announcement, IBX was 0.007% short sold according to ASIC data. It was ranked the 633rd most shorted stock on the ASX. It is now ranked as the 590th most shorted stock on the ASX with 0.006% of total shares short sold as of the latest reported data (24 December 2024).
| Other Recent Announcements from IBX | |
|---|---|
| Expanded collaboration with Siemens Healthineers to US | 28 June 2023, 8:49 |
| Imagion to complete the MagSense HER2 Phase 1 Study | 21 June 2023, 8:27 |
| Imagion Announces New CEO | 19 June 2023, 8:31 |
| 2021 Annual Report to Shareholders | 24 February 2022, 13:57 |
| Appendix 4E | 24 February 2022, 13:54 |
| Notification regarding unquoted securities - IBX | 22 February 2022, 8:15 |
| Issue of unlisted options under Equity Incentive Plan | 22 February 2022, 8:15 |
You must be logged in to post a reply.
Imagion Biosystems 